Skip to main content

Table 3 Univariate analysis of local recurrence in patients with GCTBa treated with curettage from 2008 to 2010. (n = 158)

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Clinical factors

No. of local recurrence (%)

Univariate analysis

p valueb

Site

 Extremity

29/151 (19.2%)

p = 0.746

 Trunk

1/7 (14.3%)

Campanacci grade

 Grade I

1/16 (6.3%)

p = 0.034

 Grade II

15/97 (15.5%)

 Grade III

14/45 (31.1%)

Pathological fracture at presentation

 Yes

5/26 (16.7%)

p = 0.972

 No

25/132 (18.9%)

Do you use denosumab for this case now?

 Yes

15/83 (18.1%)

p = 0.758

 No

15/75 (20.0%)

Embolization before surgery

 Yes

4/8 (50%)

p = 0.022

 No

26/150 (17.3%)

  1. aGCTB, giant cell tumor of bone
  2. bChi-square test